Neoantigen immunotherapy holds immense promise, as evidenced by clinical advancements from Nykode Therapeutics, Regeneron, and Transgene. Yet, significant hurdles exist in translating this potential into widespread cancer treatment.

Biosynth, a leader in neoantigen clinical trials, actively facilitates the neoantigen revolution. Our expertise empowers you to fast-track your neoantigen projects, making Biosynth your trusted partner for success.

What differentiates Biosynth?

· Unmatched Throughput: Our state-of-the-art facilities boast the capability to manufacture over 20 unique neoantigen peptide sets per month. This high-throughput capacity allows us to efficiently support even the most ambitious clinical trial timelines.

· GMP Expertise: Biosynth is a fully GMP-compliant facility, adhering to the strictest quality standards (EudraLex, volume 4, part II) for clinical trial materials. We ensure the safety, purity, and consistency of every neoantigen peptide we produce.

· Proven Clinical Experience: Our commitment to clinical translation is exemplified by our successful completion of Phase I studies and participation in a Phase IIB study. This experience translates into a deep understanding of the specific requirements for neoantigen-based clinical trials.